CDTX Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -30201.66% compared to Cidara Therapeutics's net margin of 14.23%. Cidara Therapeutics's return on equity of -443.37% beat Biomarin Pharmaceutical's return on equity of 6.29%.

Cidara Therapeutics has a consensus price target of --, signalling upside risk potential of 23.77%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.08 which suggests that it could grow by 47.2%. Given that Biomarin Pharmaceutical has higher upside potential than Cidara Therapeutics, analysts believe Biomarin Pharmaceutical is more attractive than Cidara Therapeutics.

Cidara Therapeutics has a beta of 1.129, which suggesting that the stock is 12.883% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.295, suggesting its less volatile than the S&P 500 by 70.544%.

Cidara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Cidara Therapeutics quarterly revenues are $302K, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. Cidara Therapeutics's net income of -$16M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, Cidara Therapeutics's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 39.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics is 1.92x versus 4.75x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Cue Biopharma has a net margin of -30201.66% compared to Cidara Therapeutics's net margin of -259.59%. Cidara Therapeutics's return on equity of -443.37% beat Cue Biopharma's return on equity of -142.28%.

Cidara Therapeutics has a consensus price target of --, signalling upside risk potential of 23.77%. On the other hand Cue Biopharma has an analysts' consensus of $4.20 which suggests that it could grow by 256.44%. Given that Cue Biopharma has higher upside potential than Cidara Therapeutics, analysts believe Cue Biopharma is more attractive than Cidara Therapeutics.

Cidara Therapeutics has a beta of 1.129, which suggesting that the stock is 12.883% more volatile than S&P 500. In comparison Cue Biopharma has a beta of 1.658, suggesting its more volatile than the S&P 500 by 65.823%.

Cidara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cue Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics pays -- of its earnings as a dividend. Cue Biopharma pays out -- of its earnings as a dividend.

Cidara Therapeutics quarterly revenues are $302K, which are smaller than Cue Biopharma quarterly revenues of $3.3M. Cidara Therapeutics's net income of -$16M is lower than Cue Biopharma's net income of -$8.7M. Notably, Cidara Therapeutics's price-to-earnings ratio is -- while Cue Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics is 1.92x versus 5.25x for Cue Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

FibroGen has a net margin of -30201.66% compared to Cidara Therapeutics's net margin of -36.87%. Cidara Therapeutics's return on equity of -443.37% beat FibroGen's return on equity of --.

Cidara Therapeutics has a consensus price target of --, signalling upside risk potential of 23.77%. On the other hand FibroGen has an analysts' consensus of $10.00 which suggests that it could grow by 1905.62%. Given that FibroGen has higher upside potential than Cidara Therapeutics, analysts believe FibroGen is more attractive than Cidara Therapeutics.

Cidara Therapeutics has a beta of 1.129, which suggesting that the stock is 12.883% more volatile than S&P 500. In comparison FibroGen has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.658%.

Cidara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FibroGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics pays -- of its earnings as a dividend. FibroGen pays out -- of its earnings as a dividend.

Cidara Therapeutics quarterly revenues are $302K, which are smaller than FibroGen quarterly revenues of $46.3M. Cidara Therapeutics's net income of -$16M is higher than FibroGen's net income of -$17.1M. Notably, Cidara Therapeutics's price-to-earnings ratio is -- while FibroGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics is 1.92x versus 0.28x for FibroGen. Usually stocks with elevated PS ratios are considered overvalued.

GlycoMimetics has a net margin of -30201.66% compared to Cidara Therapeutics's net margin of --. Cidara Therapeutics's return on equity of -443.37% beat GlycoMimetics's return on equity of --.

Cidara Therapeutics has a consensus price target of --, signalling upside risk potential of 23.77%. On the other hand GlycoMimetics has an analysts' consensus of -- which suggests that it could grow by 313.22%. Given that GlycoMimetics has higher upside potential than Cidara Therapeutics, analysts believe GlycoMimetics is more attractive than Cidara Therapeutics.

Cidara Therapeutics has a beta of 1.129, which suggesting that the stock is 12.883% more volatile than S&P 500. In comparison GlycoMimetics has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.069%.

Cidara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlycoMimetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics pays -- of its earnings as a dividend. GlycoMimetics pays out -- of its earnings as a dividend.

Cidara Therapeutics quarterly revenues are $302K, which are larger than GlycoMimetics quarterly revenues of --. Cidara Therapeutics's net income of -$16M is lower than GlycoMimetics's net income of -$9.8M. Notably, Cidara Therapeutics's price-to-earnings ratio is -- while GlycoMimetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics is 1.92x versus -- for GlycoMimetics. Usually stocks with elevated PS ratios are considered overvalued.